Mabpharm Limited (2181) announced an updated Nomination Committee Terms of Reference, originally adopted on April 10, 2019 and now amended on October 31, 2025. The document outlines the Nomination Committee's authority, membership requirements, and core responsibilities.

According to the announcement, the committee must comprise at least three members, with the majority being independent non-executive directors. At least one member must be of a different gender. The committee is chaired either by the chairman of the board or by an independent non-executive director. A quorum requires two members, including at least one independent non-executive director.

Key duties include reviewing board structure, size, and composition; identifying qualified candidates for directorships; assessing the independence of independent non-executive directors; and making recommendations on the appointment or reappointment of directors. Additional responsibilities include supporting regular board performance evaluations and reviewing the performance and suitability of senior management.

The announcement confirms that at least one committee meeting will be held each year, or more frequently as required by applicable regulations. Meeting proceedings are recorded, and the final version of meeting minutes is circulated among all members. The updated Terms of Reference are available on relevant websites, and the document notes that in the event of any ambiguity, the Chinese version prevails.